Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation by Dietz, A.C. et al.
Current Knowledge and Priorities for Future Research in Late
Effects after Hematopoietic Cell Transplantation for Inherited
Bone Marrow Failure Syndromes: Consensus Statement from
the Second Pediatric Blood and Marrow Transplant Consortium
International Conference on Late Effects after Pediatric
Hematopoietic Cell Transplantation
Andrew C. Dietz 1,*, Parinda A. Mehta 2,3, Adrianna Vlachos 4, Sharon A. Savage 5,
Dorine Bresters 6, Jakub Tolar 7, Farid Boulad 8, Jean Hugues Dalle 9, Carmem Bonfim 10,
Josu de la Fuente 11,12, Christine N. Duncan 13, K. Scott Baker 14, Michael A. Pulsipher 1,
Jeffrey M. Lipton 4, John E. Wagner 7, Blanche P. Alter 5
1 Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, California
2 Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center,
Cincinnati, Ohio
3 Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
4 Hofstra Northwell School of Medicine, Feinstein Institute for Medical Research, Cohen Children’s Medical Center, Division of Hematology/Oncology and
Stem Cell Transplantation, New Hyde Park, New York
5 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
6 Willem-Alexander Children’s Hospital, SCT Unit, Leiden University Medical Center, Leiden, The Netherlands
7 Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
8 Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Division of Pediatric Hematology/Oncology, New York
Presbyterian Hospital, Weill Cornell Medical College, New York, New York
9 Université Paris 7, Hôpital Robert-Debré, Service d’hémato-immunologie, Paris, France
10 Hospital de Clinicas, Federal University of Parana, Curitiba, Brazil
11 Section of Paediatrics, Imperial College, London, United Kingdom
12 Department of Paediatric Haematology, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
13 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts
14 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
Article history:
Received 14 January 2017











A B S T R A C T
Fanconi anemia (FA), dyskeratosis congenita (DC), and Diamond Blackfan anemia (DBA) are 3 of the most common
inherited bone marrow failure syndromes (IBMFS), in which the hematologic manifestations can be cured with
hematopoietic cell transplantation (HCT). Later in life, these patients face a variety of medical conditions, which
may be a manifestation of underlying disease or due to pre-HCT therapy, the HCT, or a combination of all these
elements. Very limited long-term follow-up data exist in these populations, with FA the only IBMFS that has
specific published data. During the international consensus conference sponsored by the Pediatric Blood and
Marrow Transplant Consortium entitled “Late Effects Screening and Recommendations following Allogeneic
Hematopoietic Cell Transplant (HCT) for Immune Deficiency and Nonmalignant Hematologic Disease” held
in Minneapolis, Minnesota in May of 2016, a half-day session was focused specifically on the unmet needs
for these patients with IBMFS. A multidisciplinary group of experts discussed what is currently known, out-
lined an agenda for future research, and laid out long-term follow-up guidelines based on a combination of
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evidence in the literature as well as expert opinion. This article addresses the state of science in that area as
well as consensus regarding the agenda for future research, with specific screening guidelines to follow in
the next article from this group.
© 2017 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights
reserved.
INTRODUCTION
Fanconi anemia (FA), dyskeratosis congenita (DC), and
Diamond Blackfan anemia (DBA) are 3 of the most common
inherited bone marrow failure syndromes (IBMFS), for which
the hematologic manifestations can be cured with hemato-
poietic cell transplantation (HCT). With improvements in HCT
over time, there are larger numbers of survivors for whom
we need to understand long-term health. Many of these pa-
tients ultimately face a variety of medical conditions, which
may be a manifestation of underlying disease or due to their
pre-HCT therapy, their HCT, or a combination of all these el-
ements. This is complicated, as there are limited data
regarding late effects in these populations, which impairs our
ability to propose approaches that may modify these late
effects. An international consensus conference sponsored by
the Pediatric Blood and Marrow Transplant Consortium en-
titled “Late Effects Screening and Recommendations following
Allogeneic Hematopoietic Cell Transplant (HCT) for Immune
Deficiency and Nonmalignant Hematologic Disease” was held
in Minneapolis, Minnesota in May of 2016. During this con-
ference, a half-day session focused specifically on the unmet
needs for patients with an IBMFS. The goal was to create better
understanding about what is already known, define re-
search gaps, and establish screening recommendations for
long-term complications in these patient populations. A mul-
tidisciplinary group of experts coordinated multiple phone
calls ahead of the conference and met in person at the con-
ference with the focus on the following 6 questions: (1) what
about the nature of each disease predisposes patients to late
effects, (2) what treatments for each disease predispose pa-
tients to late effects, (3) what current HCT methods in each
disease predispose patients to late effects, (4) what is known
about current HCT outcomes in each disease, (5) what is
known about long-term follow-up with or without HCT in
each disease, and (6) what should be our agenda for future
research based on the most significant gaps in the litera-
ture for each disease?
We report here the results of those discussions specifi-
cally related to FA, DC, and DBA.
FA
FA is an IBMFS characterized by birth defects, progres-
sive bone marrow failure (BMF), and predisposition to cancer
and myelodysplastic syndrome (MDS). The inheritance is pri-
marily autosomal recessive, except FANCB, which is X-linked,
and FANCR (RAD51), which is dominant. There at least 21
genes whose gene products combine in the FA/BRCA DNA
repair pathway (Figure 1). After DNA damage, the proteins
produced by FANCA, FANCB, FANCC, FANCE, FANCF, FANCG,
FANCL, and FANCM form the core complex, which is re-
quired for ubiquitination of the I and D2 proteins, which are
in turn required for the downstream complex of FANCD2-
ubi, FANCI-ubi, and FANCD1/BRCA2, FANCJ/BACH1/BRIP1,
FANCN/PALB2, FANCO/RAD51C, FANCP/SXL4, FANCQ/ERCC4,
FANCR/RAD51, FANCS/BRCA1, FANCU/XRCC2, and FANCV/
REV7 to form foci for DNA repair [1-5].
Acute myeloid leukemia (AML) and solid tumors, including
squamous cell carcinoma (SCC) of head and neck and genital
region, are the most common malignancies in these patients. The
relative risk of AML is increased approximately 500-fold with
a cumulative incidence of ~10% by age 50 years, with most in-
dividuals diagnosed between the ages of 15 and 35 years [6-9].
Solid tumors may be the first manifestation of FA in individu-
als who have no birth defects and have not experienced BMF.
Head and neck SCC (HNSCCs) are the most common solid tumor
in individuals with FA. The risk is 700- to 900-fold that of the
general population of comparable age and sex. Compared with
the general population, HNSCCs in FA occur at an earlier age (20
to 40 years), present at an advanced stage, and are difficult to
treat given limited tolerance to standard chemotherapy and ra-
diation treatments. In contrast with the general population,
HNSCC in patients with FA is in the oral cavity, not the orophar-
ynx, and may not be associated with human papillomavirus [10].
In addition, specific subtypes of FA have increased predisposi-
tion to a unique set of malignancies. Biallelic pathogenic variants
in BRCA2 are associated with early-onset acute leukemia and solid
tumors [11-13]. The cumulative probability of any malignancy
in patients with biallelic mutations in FANCD1/BRCA2 is 97% by
6 years of age, including AML, medulloblastoma, and Wilms
tumor [13]. Similar malignancies are also associated with patho-
genic variants in FANCN/PALB2 [14]. This increased risk of primary
malignancy adds to the burden of secondary malignancies (leu-
kemia or solid tumors) that may arise after HCT. One study
indicated a 4.4-fold higher risk of SCC in patients with FA who
had undergone HCT compared with those who had not under-
gone HCT, with SCC occurring at younger ages in the patients
who had undergone HCT [15].
In addition to DNA repair issues [2], there is evidence that
FA mutations may lead to increased risk of cancer because
of the involvement in other key biological pathways. Studies
have implicated excessive reactive oxygen species in FA cells
(linked to increased leukemia or SCC) [16,17], mitochon-
drial defects [18,19] (including a block in mitophagy) [20],
and immune function abnormalities in some patients with
Figure 1. FA/BRCA DNA damage response pathway. This figure is updated
from [30].
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FA [21,22], suggesting that impaired immune surveillance may
contribute to cancer susceptibility in patients with FA.
Chemotherapy and/or radiation used during HCT adds
tissue injury and organ damage, which can be particularly
severe in patients with a defect in DNA repair and genomic
instability. The inherent defective DNA repair in somatic lin-
eages, along with an increased susceptibility to complications
of HCT, clearly affect long-term survival of patients with FA.
Patients with FA who progress to severe marrow failure
may have been treated in the past with growth factor (granu-
locyte colony–stimulating factor [G-CSF]) and/or transfusion
support. Multiple transfusions lead to iron overload in liver
and heart before HCT, potentially increasing the risk of organ
damage (eg, sinusoidal obstruction syndrome [SOS]) from che-
motherapy and/or radiation used in the conditioning regimen
for HCT, which in turn affect overall HCT outcomes.
Androgens remain a treatment modality for BMF in pa-
tients with FA. Individuals with FA receiving androgens are
at increased risk of side effects, which include virilization and
liver toxicity such as elevated liver enzymes, cholestasis,
peliosis hepatis (vascular lesion with multiple blood-filled
cysts), and hepatic tumors (benign adenomas or malignant
carcinomas); these issues have been associated with in-
creased risk for treatment-related mortality during HCT
[23,24]. Administration of oral androgens improves blood
counts (red cell and platelets) in approximately 50% of in-
dividuals with FA and administration of G-CSF improves the
neutrophil count in some; however, HCT is currently the only
curative therapy for the hematologic manifestations of FA (ie,
severe marrow failure, MDS, or leukemia).
Clinically significant chemotherapy and radiation sensi-
tivity related to impaired DNA damage repair have historically
made allogeneic HCT for patients with FA extremely chal-
lenging [25-27]. In addition, patients with FA and AML who
receive cytoreduction before HCT may accumulate addition-
al organ damage. Chronic graft-versus-host disease (GVHD)
of mouth and/or genitourinary tract, has been associated with
increases in the baseline risk of SCC [28]. HCT also in-
creases the risk of secondary solid tumors and therapy-
related MDS or leukemias, as it does the non-FA population
but to greater degree [15,29]. Renal insufficiency is rare in
patients with FA, despite the fact that about one-quarter of
FA patients have structural abnormalities involving kidneys
and urinary tract [30]. Renal function may be compromised
during and after HCT because of chemotherapy and
calcineurin inhibitors. There are little data on long-term kidney
outcomes in these high-risk patients.
HCT is ideally performed before onset of MDS or AML and
before multiple transfusions [31-33]. HCT approaches and out-
comes have improved significantly for patients with FA over
the last 3 decades [34-36]. Initial methods for HCT for FA in
the late 1970s and early 1980s were associated with exces-
sive toxicity and high mortality rates [37]; since then, better
understanding of the biology of the disease led to use of lower
doses of total body irradiation (TBI), cyclophosphamide,
fludarabine and antithymocyte globulin (ATG) as a common
HCT conditioning regimen for patients with FA.
Conditioning regimens containing irradiation are a risk
factor for post-transplantation malignancy in patients with
FA, but the comparative effects of radiation with other medi-
cations is not well understood [38,39]. A number of reports
have also shown increased risk of subsequent malignancy as-
sociated with chronic GVHD in FA [28,36]. T cell depletion
of the donor graft is clearly effective in largely eliminating
severe acute and chronic GVHD; however, post-transplantation
lymphoproliferative disorder is a well-known complication
of HCT conditioning regimens containing ATG or those using
ex vivo T cell depletion and has been reported in patients with
FA after HCT.
GVHD and graft rejection are 2 major challenges in HCT
for patients with FA. Addition of ATG and T cell depletion of
donor grafts have decreased GVHD, and the addition of
fludarabine has decreased graft rejection. This allowed elim-
ination of TBI from the preparative regimen for FA
transplantation from matched sibling donors [40-44]. Five-
year survival after a matched sibling transplantation is now
approximately 90%. Recent results for unrelated donor trans-
plantation similarly show improvements [34-36,42]. With
better HCT outcomes, more patients with FA have survived
to adulthood and long-term side effects of HCT, including the
increased risk of secondary cancers, have become more
apparent.
Reports from Brazil, Germany, and the Netherlands in
smaller cohorts have demonstrated that good outcomes can
be achieved in unrelated donor setting for patients with FA
using non-TBI approaches [45-47]. A more recent prospec-
tive multi-institutional US study showed that a radiation-
free approach led to overall and disease-free survival
comparable to those associated with radiation-containing regi-
mens; however, direct comparison with TBI-based approaches
and comparison of late effects with TBI versus non-TBI ap-
proaches has not been performed [48].
HCT can restore long-term hematopoiesis and cure the he-
matologic complications of FA; however, when compared with
age-matched controls, these patients do not achieve com-
plete health or normal life expectancy. Patients continue to
remain at risk of long-term complications either from
transplantation-related factors or secondary to FA-related
complications, including those related to congenital anoma-
lies, endocrinopathies, and increased cancer susceptibility
(Table 1) [9,49]. Tables 1 and 2 describe overall classes of late
effects in patients with FA and discuss findings of specific
studies.
Recommendations for follow-up of patients with FA after
transplantation have been limited in the past; more re-
cently, newer studies are adding to the available data and will
further refine current recommendations [36,39,47,50,52,53].
Endocrinopathies, including thyroid dysfunction, growth
hormone deficiency, and glucose intolerance, are common in
patients with FA independent of HCT. In a series of 120 pa-
tients with FA, 48% of patients who had not undergone HCT
and 53% of patients who had undergone HCT were found to
have hypothyroidism [51]. Glucose intolerance/insulin re-
sistance has been reported in 40% to 80% of patients with FA,
Table 1
Complications in Patients with Fanconi Anemia
System Abnormalities
Endocrine Poor growth, growth hormone deficiency, glucose
metabolism, thyroid, osteoporosis, hypogonadism,
and infertility




Hearing Sensorineural hearing loss
Ophthalmology Cataracts, dry eyes, retinitis
The etiology of these complications is multifactorial and can be associated
with aging alone; however, they can also be exacerbated by HCT prepara-
tive regimens, GVHD prophylaxis, GVHD, and antibiotics.
728 A.C. Dietz et al. / Biol Blood Marrow Transplant 23 (2017) 726–735
independent of HCT. A more recent report showed a similar
high incidence of hypothyroidism (45%), with one-half of these
patients having evidence of hypothyroidism before HCT [39].
In addition, 9 of 18 patients (50%) who received a TBI-
based regimen had insulin resistance/insulin-dependent
diabetes mellitus, and 30% of patients developed
hypertriglyceridemia. About two-thirds (67%) of postpuber-
tal evaluable males also showed evidence of gonadal
dysfunction, similar to prior reports. In this cohort, among
18 patients who received TBI-based regimens, 4 patients also
developed cataracts and 5 developed conductive hearing loss.
Female patients with FA, even without transplantation,
have shortened reproductive life with late menarche, early
menopause, and subfertility [54]. Patients with FA undergo-
ing HCT are at high risk of gonadal dysfunction and infertility
after high-dose alkylating agent–based chemotherapy or high-
to moderate-dose TBI-based regimens. Pregnancy after HCT
for FA is relatively rare. Among 285 female patients 16 years
or older with FA who underwent HCT with cyclophosphamide/
TBI or cyclophosphamide (n = 3), 10 became pregnant, though
these data are limited by lack of information about desire for
pregnancy [55].
An Outline for Future Research in FA
Patients with FA who undergo HCT face much brighter
prospects today than in years past. We have come a long way
in terms of optimizing transplantation outcomes for FA and
further improvement in survival may result from a better un-
derstanding of late effects resulting from the transplantation
itself. This remains challenging as we may not be able to fully
separate the progressive problems inherent to the underly-
ing disease from those related to or exaggerated by HCT. FA
is the most-studied IBMFS, forming the basis for our under-
standing of other marrow failure disorders and transplantation
strategies for them. Knowledge of late effects in this popu-
lation will inform future therapies. Now that we have achieved
survival rates of 90% or more in patients with FA who have
undergone transplantation for marrow failure from sibling
donors and over 80% from matched unrelated donors, further
optimization of therapy to alter the risk of late effects should
become a focus for future study. Rarity of many subtypes of
the disease may limit our ability to understand the natural
history of different subtypes of FA, but this must be studied,
as there will assuredly be differences in long-term out-
comes based upon subtype-specific biology. A number of key
research priorities moving forward have been identified, in-
cluding the following:
1. Large cohorts of patients who had not undergone HCT from
FA centers with thorough longitudinal follow-up should
be combined to further solidify data regarding the natural
history of the disease and yield a robust dataset, against
which we will be able to compare the patients with FA
who undergo HCT. This, in turn ,will lead to a more mean-
ingful comparison in contrast to using HCT cohorts of all
nonmalignant conditions or those undergoing HCT for ma-
lignant conditions, as the preparative regimens, intensity,
and chemotherapy/radiation tolerance are significantly dif-
ferent for patients with FA.
2. Data from the Center for International Blood and Marrow
Transplant Research (CIBMTR) and the European Society
for Blood and Marrow Transplantation (EBMT) should be
combined to increase the number of patients to quanti-
fy late effects after HCT. This effort may be associated with
inherent limitations of different approaches utilized for
HCT, especially fundamental differences such as T cell de-
pletion or differences in GVHD prophylaxis, which can
change late effects significantly related to the altered risk
of GVHD, viral infections, and/or post-transplantation
lymphoproliferative disorder and, in turn, secondary
cancers. The depth of data collection is always an issue
with any registry studies compared with prospective
studies. It will be important to follow patients treated with
the most recent approach of chemotherapy-only prepara-
tive regimens to study both short- and long-term effects
compared with the historical TBI groups.
Table 2
Late Effects after HCT in Patients with FA
Reference Number Main Findings
Bonfim et al. [36] 157 Population was a median 9 years in follow-up mostly conditioned without radiation, with HCT from a
matched related donor, and with chronic GVHD in about one-third. Late effects included malignancy in 15,
hypothyroidism in 29, gonadal dysfunction in 49, neurologic dysfunction in 25, and hearing loss in 15.
Rosenberg et al. [15] 117 Population had 508 person-years of follow-up mostly conditioned with radiation and one-half with HCT from
a matched related donor and one-half from a matched unrelated donor. Late effects included non-SCC deaths
in 48 and SCC in 11. Risk of SCC was 4.4-fold higher after HCT versus FA patients without HCT and SCC
occurred at younger ages. GVHD was identified as a significant risk factor.
Barnum et al. [50] 44 Population was a median 3.1 years in follow-up mostly conditioned with radiation, with HCT from a matched
unrelated donor or cord blood, and with chronic GVHD in 5%. Late effects included hypothyroidism in 57%,
gonadal dysfunction in 27%, short stature in 50%, vitamin D deficiency in 71%, insulin resistance in 38%, and
low bone mineral density in 43%.
Rose et al. [51] 39 Population details were limited, though most were conditioned with radiation. Identified endocrine issues in
those after HCT included hypothyroidism in 65% of children and 43% of adults, growth hormone deficiency in
22% of children and 25% of adults, gonadal dysfunction in 40% of children and 43% of adults, hyperglycemia in
30% of children and 9% of adults, and low bone mineral density in 13% of children and 12% of adults.
Anur et al. [39] 22 Population was a median 7.4 years in follow-up mostly conditioned with radiation, with HCT from an
alternative donor, and without chronic GVHD reported. Late effects included malignancy in 2, hypothyroidism
in 10, hyperglycemia in 10, gonadal dysfunction in 12, cataracts in 4, and hearing loss in 5. TBI was a risk
factor for late effects.
Petryk et al. [52] 20 Population was a median 2.8 years in follow-up all conditioned with radiation and with chronic GVHD in 15%.
Late effects included lower height and body mass index than controls, lower lean body mass, hypothyroidism
in 6, gonadal dysfunction in 3, and lower bone mineral density than controls.
Sanders et al. [53] 15 Population was a median 20 years in follow-up mostly conditioned without radiation, with HCT from a
matched related donor, and with chronic GVHD in about one-third. Late effects included malignancy in 2 with
other reported outcomes mixed in with non-FA aplastic anemia patients.
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3. Basic research to find the common links or define the dis-
parity between etiology and pathogenesis of drivers of
BMF, endocrine problems, leukemogenesis, and carcino-
genesis in FA should continue to make progress. This, in
turn, will drive the improvements in future HCT and gene
therapy efforts to improve global patient outcomes.
DC
DC is a multisystem disorder caused by abnormal telo-
mere biology. There is a phenotypic spectrum that ranges from
the classic mucocutaneous triad of oral leukoplakia, reticu-
lar skin changes, and abnormal nails to patients with short
telomeres and only isolated physical findings [56]. Patients
with DC and the related telomere biology disorders (TBD) may
present with 1 or a combination of BMF, pulmonary fibro-
sis, HNSCC, or liver disease. It is important to note that the
features of DC change over time and can vary even within
the same family. Leukocyte telomeres less than the first per-
centile for age, measured by flow cytometry with in situ
hybridization, are diagnostic of DC [57].
Autosomal dominant, autosomal recessive, and X-linked
recessive inheritance patterns have been identified as the
causes of DC/TBD and resultant very short telomeres for age.
The known genes include ACD, CTC1, DKC1, NAF1, NHP2, NOP10,
PARN, POT1, RTEL1, STN1, TERC, TERT, TINF2, and WRAP53
(Figure 2). These 14 genes currently account for about 70%
of patients clinically diagnosed with DC [56,58-63]. The
genotype/phenotype associations are complex and not fully
understood yet [56,58], although there are some correla-
tions between autosomal recessive and X-linked disease, as
well as autosomal-dominant pathogenic variants in TINF2
being associated with more severe childhood-onset disease.
For example, autosomal-dominant DC/TBD caused by patho-
genic variants in TERT, RTEL1, or PARN are associated with
adult-onset disease, whereas biallelic or homozygous vari-
ants in these genes cause severe DC early in life [59]. A
comprehensive diagnostic and clinical care guidelines book
has recently been published (www.dcoutreach.org/guidelines).
Telomeres are a nucleoprotein complex that cap chromo-
some ends and are essential for chromosomal stability.
Telomeres shorten with each cell division because of the in-
ability of DNA polymerase to replicate the 3‘ ends of DNA and
thus telomere length is a marker of normal aging. The 6
protein shelterin complex serves to protect telomeric ends
and telomerase holoenzyme complex extends the nucleo-
tide repeats [57]. When telomeres reach a critically short
length, cellular crisis or senescence is triggered. Cancer cells
upregulate telomerase, TP53, Rb, and other pathways that
allow them to continue to divide despite having critically short
telomeres. Patients with DC/TBD have reduced cellular rep-
licative capacity because of the short telomeres caused by their
underlying genetic disorder. Pathogenic variants in the
telomerase holoenzyme complex limit the ability of cells to
extend telomeres, and those in proteins essential in telo-
mere protection result in the loss of telomeres; thus, patient
cells lose the ability to replicate sooner than would be ex-
pected for their age [59].
The predominant clinical features of DC include BMF,
cancer risk, pulmonary fibrosis, and liver cirrhosis
[56,58,64,65]. Additional features include enteropathy, en-
terocolitis, arteriovenous malformations, osteoporosis,
avascular necrosis, and immunodeficiency [56,65]. Each of
these diagnoses may, in fact, represent the presenting sign
of DC in patients without the classic triad. BMF may be seen
between 50% and 90% of patients depending on the cohort
by the age of 40 [56,58,64]. Cancer has been described in
about 15% of all patients. With a median onset of 37 years,
approximately 35% of patients will develop cancer by the age
of 50. The risk of cancer was reported to be 11-fold com-
pared with the general population and can include MDS (more
than 2000-fold increased risk), AML (200-fold), and HNSCC
(1154-fold, primarily tongue cancer) [7,56]. The increased risk
of primary malignancy is amplified by secondary cancers that
can be seen after HCT.
With the development of BMF, patients with DC can be
treated with standard supportive care measures, including
red blood cell or platelet transfusions, growth factors, and an-
timicrobial prophylaxis against infections. Generally, these are
short-term measures and none represent curative options for
BMF. In general, excessive transfusions of red cells or plate-
lets should be avoided as they can complicate future HCT
through allogeneic immunization and through iron over-
load from the red blood cells. A special note regarding the
growth factor G-CSF is that it should not be given in combi-
nation with androgens because of the risk of splenic rupture
[66]. Importantly, immunosuppressive therapy typically used
in acquired aplastic anemia is unlikely to be successful with
more cases being refractory, relapsing, or progressing to clonal
evolution and may only delay or complicate other treat-
ments [58,65].
Androgens, including oxymetholone and more recently
danazol, are hormones that have been shown to stabilize and
improve peripheral blood counts in DC similar to the effica-
cy they have shown in FA [56,58,65]. The treatment duration
and follow-up have been too short to draw strong conclu-
sions regarding prolonged value and long-term side-effects.
Side effects of androgens include impaired liver function, liver
tumors, virilization, and behavioral problems. Patients with
DC may actually be even more responsive to these hor-
mones than those with FA [65], but they may also develop
more side effects because of increased sensitivity [67]. The
more recently used androgen danazol may ultimately have
fewer side effects and improved efficacy in DC; 1 small study
suggested that there may be modulation of TERT gene ex-
pression with increase in telomerase [65,68]. It is unknown
whether these effects will benefit organ dysfunction aside
from BMF.
Figure 2. Schematic of telomere biology. The relevant genes are listed in
the text, and the figure includes proteins that have not yet been reported
to be associated with disease. [Wegman-Ostrosky T, Savage, SA. The ge-
nomics of inherited bone marrow failure: from mechanism to the clinic. Br
J Haematol. In press.]
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The development of cancer in patients with DC can be par-
ticularly difficult to manage and requires attention to cancer-
specific therapy, which may need tailored. Exposure to
chemotherapy and radiation can result in increased risk of
prolonged cytopenias as well as pulmonary and hepatic tox-
icities. MDS or AML would be an indication to proceed to HCT,
though with concern for additive toxicities of treating with
pre-HCT chemotherapy [56,65]. Non-BMF manifestations, such
as pulmonary fibrosis and liver cirrhosis, whether from
primary disease or secondary to therapies, are managed with
standard supportive care measures specific to the dysfunc-
tional organ. Both lung and liver transplantation have been
reported successfully in DC patients and should be given ap-
propriate consideration [69,70]. Subsequent need for
immunosuppression may impact already underlying immu-
nodeficiency and risk of cancer development. Attempts at
telomere elongation and telomerase activation are being
studied in the laboratory, but it is too early to know the po-
tential impact of these therapies [71].
HCT represents the only current curative treatment for
BMF, MDS, and leukemia in patients with DC. However, un-
derlying pulmonary and hepatic disease may predispose these
patients to increased transplantation-related morbidity and
mortality, and HCT may result in increased toxicity in the lungs
and liver compared with other transplant recipients [56,65].
Additionally, HCT will not help tissues other than the bone
marrow, and the interaction between underlying disease and
complications of HCT is not well understood. As mentioned
above, exposure to chemotherapy and radiation can result in
increased risk of prolonged cytopenias as well as pulmo-
nary and hepatic toxicities. Because of the underlying
sensitivity of these patients, early myeloablative condition-
ing transplantations resulted in significant early and late
mortality, with fewer than 30% of patients surviving 10 to 15
years after HCT [64,72,73]. There has been an attempt to
modify protocols to have reduced-intensity conditioning (RIC)
by lowering or eliminating alkylating agents and radiation.
The development of RIC protocols with fludarabine, lower
doses of cyclophosphamide, lower doses of TBI, and sero-
therapy with ATG or alemtuzumab subsequently showed
improved early outcomes, with 9 patients out of 11 surviv-
ing [72,74,75]. A nonradiation regimen with fludarabine,
lower-dose melphalan, and alemtuzumab resulted in 5 of 7
patients alive in early follow-up [76]. There has also been
success in the haploidentical setting with a similar RIC ap-
proach and the use of ex vivo T cell depletion [77].
Despite early success with RIC regimens, there is still a
significant amount of late mortality after HCT for DC, pri-
marily from pulmonary complications. In a systematic review
of survival after both myeloablative and RIC HCT in DC, 109
patients reported in the literature had an overall survival of
57% at 5 years and 23% at 10 years [64]. This report con-
firmed improvement in early survival after the year 2000,
when transplantation was performed before the age of 20 and
when the donor was a matched sibling, but with no real
change in long-term survival. Although infection, graft failure,
and hemorrhage dominate early causes of mortality, pulmo-
nary disease, liver disease, and vascular complications
dominate late mortality. These data are affected by a publi-
cation bias, a changing definition of telomere disease over
the last few years, and the possibility that those with BMF
have more severe forms of DC [64]. Conversely, some pa-
tients with DC/TBD phenotype and “isolated” BMF have been
diagnosed and underwent transplantation as idiopathic severe
aplastic anemia, with results different from those with the
severe DC-associated phenotype; ie, “classical” DC. Those pa-
tients may also have the same poor prognosis as the other
DC patients and worsen the overall results of patients who
underwent transplantation for apparently acquired severe
aplastic anemia.
It is clear, however, that HCT studies in DC need to look
beyond traditional 3- to 5-year endpoints and aim to under-
stand and, potentially, prevent late mortality. To further improve
outcomes, some investigators are attempting to eliminate ra-
diation and alkylating agents and use only fludarabine with
ATG [78] or alemtuzumab (ongoing multi-institution trial based
out of Boston Children’s Hospital [www.clinicaltrials.gov,
NCT01659606]). Although there is some promise in early results
with these approaches, larger numbers and longer follow-up
are needed to establish whether these approaches lead to im-
proved outcomes.
There are no dedicated studies examining long-term
follow-up in this population to date. The systematic review
mentioned above and published in 2016 reviewed all case
reports and case series that include late complications, which
are primarily pulmonary disease, liver disease, and vascular
complications [64]. There is a lag time inherent in survivor-
ship studies. Although further development of studies could
examine long-term follow-up in patients treated with earlier
conditioning regimens, fully understanding the impact of
recent RIC protocols will take more time.
An Outline for Future Research in DC
Reports on both short- and long-term outcomes in DC lag
far behind the number of reports that now exist for FA. A
number of key research priorities moving forward have been
identified, including the following:
1. Reports on long-term follow-up for those patients where
the short-term outcomes have already been reported
should be included, as should collaboration on collec-
tive retrospective studies with much greater time after HCT.
More importantly, prospective trials should include pa-
tients with DC who either undergo or do not undergo HCT
and require follow-up beyond the traditional 3- to 5-year
endpoints previously reported.
2. Given the rarity of this disease, international collabora-
tion will be required, through mechanisms that already
exist such as the CIBMTR and EBMT, as well as through
newly formed consortia. An example of this is the Clini-
cal Care Consortium for Telomere Associate Ailments
established and formalized within the last few years. There
is a need for multiple comparisons over time that can
include the comparison between those with DC who
undergo HCT with those who do not undergo HCT, as well
as with patients who undergo HCT for other reasons, and
even the general population. As in other areas, knowl-
edge of long-term outcomes will inform future directions
for the treatment of these patients.
3. Ongoing biological and translational studies that can lead
to increased understanding of the genotype-phenotype
correlation to better understand natural history and that
may alter the role of HCT in the long run are needed. The
spectrum of DC-related TBDs is only just being under-
stood and long-term natural history studies of patients
with very short telomeres and pathogenic variants in telo-
mere biology genes need to be conducted. Given the
growing number of genes associated with DC/TBDs, large,
international, collaborative studies are required to better
understand the complications before and after HCT.
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DBA
DBA is a rare IBMFS frequently responsive to long-term
corticosteroid therapy but often needing chronic red cell trans-
fusions. The disorder is characterized by macrocytic anemia,
reticulocytopenia, and a selective decrease or absence of ery-
throid precursors in an otherwise normocellular bone marrow.
Congenital physical abnormalities, including thumb abnor-
malities (classically a triphalangeal thumb), craniofacial
defects, and cleft lip/palate as well as short stature, are seen
in one-half of the patients with DBA. The inheritance is pri-
marily autosomal dominant, due to mutations in genes for
ribosomal proteins; approximately 50% are de novo. Muta-
tions in genes involved in the 40s small ribosomal subunit
have been reported in RPS19, RPS10, RPS26, RPS24, RPS17,
RPS29, RPS28, RPS27, and RPS20. Those in the 60s large ribo-
somal subunit include RPL11, RPL5, RPL35A, RPL26, RPL15,
RPL31, and RPL27 (Figure 3). Rare patients with clinical DBA
had mutations in X-linked GATA1 and TSR2 [79,80]. DBA is
also a cancer-predisposition syndrome [81].
Generally, patients receive transfusions until the diagno-
sis is confirmed and remain on transfusion therapy,
withholding corticosteroids, for the first year of life if the blood
product supply is readily available and safe and reliable venous
access is attainable. At around 1 year of age, after vaccina-
tions are completed and the neurodevelopmental risk of
corticosteroids is mitigated, a corticosteroid trial is initi-
ated. Corticosteroid doses are weaned to the lowest possible
dose to maintain an adequate hemoglobin level. The only
known cure for the anemia of DBA is HCT, although approx-
imately 20% of patients will enter a durable remission from
either corticosteroid or chronic transfusion therapy [82].
Eighty percent of DBA patients initially respond to corti-
costeroid therapy, but one-half of these patients will lose their
steroid responsiveness or need to discontinue therapy because
of excessive corticosteroid toxicity, such as cataracts, patho-
logic fractures, poor linear growth, etc [83]. Osteopenia and
other corticosteroid side effects may be present at the time
the patient resumes chronic transfusion therapy and may be
exacerbated by endocrinopathies resulting from iron over-
load. Thus, specific attention to endocrine function (thyroid,
adrenal, gonadal, pituitary, etc.) should be part of any pre-
and post-HCT evaluation. In fact, it is recommended that all
patients with DBA are followed routinely by an endocrinolo-
gist, regardless of treatment. The incidence of osteopenia is
not well reported in DBA; nor is the use of bisphosphonate
therapy [84]. However, pathologic fractures have been seen
in up to 20% of patients [83]. There are normal values for bone
densitometry down to age 5 years. Similarly, the use of growth
hormone has not been well documented but has been re-
ported to be effective in some DBA patients [85]. Osteosarcoma
has also been reported, with an observed to expected ratio
of over 30 [86]. It is not clear if the use of growth hormone
and the incidence of osteosarcoma are linked; however, 2 pa-
tients who developed osteosarcoma had been on growth
hormone therapy, 1 of these after HCT.
To date, registries in many countries with granular infor-
mation have been able to provide outcome data with regards
to HCT. The North American Diamond Blackfan Anemia Reg-
istry (DBAR) with over 25 years of enrollment has 100 patients
who have undergone 102 transplantations; data from these
patients are being analyzed currently. The Italian Associa-
tion of Paediatric Haematology and Oncology-DBA and HCT
Registries analyzed 30 allogeneic transplantations from 9
centers [87]. The United Kingdom DBA registry has 10 pa-
tients reported who have undergone HCT (de la Fuente J;
unpublished data). Registries from France and Germany have
data linked to CIBMTR. A current CIBMTR study of 64 pa-
tients is underway with 7 years of follow-up.
The DBAR previously reported improved outcomes for pa-
tients undergoing HCT at an age younger than 10 years [88,89].
As the majority of the HCT reported were done for transfu-
sion dependence, 1 of the main issues in these patients is
hypothesized to be the impact of iron burden on transplan-
tation outcome. Of importance is that cardiac iron burden in
DBA patients appears to be greater than in thalassemia pa-
tients undergoing chronic transfusion therapy, with increased
cardiac deposition disproportionate to total body iron burden
[90]. Aside from cardiac iron overload, iron burden result-
ing in multiple endocrinopathies may create comorbidities
in these patients. Therefore, HCT outcomes may be linked to
transfusion therapy and the subsequent iron burden rather
than directly to the actual age of the patient or the under-
lying disease. Careful evaluation and management of iron
overload should be pursued before transplantation and will
likely need to be continued after HCT. Despite a paucity of
data to support a direct relationship between transplantation-
related morbidity/mortality, aggressive pre-HCT iron chelation
can certainly reduce the iron burden to a liver iron concen-
tration of less than 3 mg/g dry weight and may potentially
decrease the risk of hepatic SOS and infection. Post-HCT ag-
gressive phlebotomy may be necessary to decrease any
remaining iron burden, as routine phlebotomy for follow up
laboratory evaluation and time will not significantly reduce
the iron burden exacerbated by necessary pre-engraftment
red cell transfusions. The post-HCT management of iron
burden appears to be vital to long-term survival as deaths
due to cardiac iron overload have been reported to the DBAR
as late as 5 to 7 years after transplantation (unpublished data),
suggesting that the duration of an elevated iron burden ex-
posure during, as well as before, HCT is critical.
As summarized above, DBA is caused by a mutation (or
deletion) in 1 of 17 small or large subunit ribosomal protein
genes in 65% to 75% of patients [91]; less than 1% of the cases
are inherited in an X-linked recessive manner and are due
to mutations in the transcription factor GATA1 [80] or the pu-
tative RPS26 chaperone TSR2 [79]. Thus, it is vital to document
the genotype of the patient and determine that the donor
sibling or related donor is not also affected. Unfortunately,
there may be incomplete penetrance with variable
expression, and genotypically positive donors may be
hematologically normal. In the absence of a known genotype,
Figure 3. Genes involved in ribosomal biogenesis in Diamond Blackfan
anemia.
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DBA-associated birth defects, macrocytosis, or an elevated fetal
hemoglobin or erythrocyte adenosine deaminase activity may
reveal that a sibling is likewise affected and should not serve
as a donor [92]. As well, there are no genotype/phenotype
correlations for cancer risk or of the likelihood of a dispro-
portionately elevated cardiac iron burden. Thus, there is no
reliable predictor of these predispositions that may influ-
ence transplantation decision-making. There is, however, a
possible correlation of immunodeficiency and neutropenia
in patients with a mutation/deletion of RPL35A (unpub-
lished data). These patients often have more infections and
may require G-CSF and immunoglobulin therapy continu-
ously or intermittently. The complications associated with this
genotype may warrant an earlier consideration of HCT.
The deaths reported to the DBAR in past years were mostly
due to transplantation-related mortality, such as GVHD and
SOS. In more recent years, the deaths of patients who have
not undergone HCT have been mainly due to complications
from iron overload. As the patients in the DBAR are aging,
more cancers are also being reported. Five cancers have now
been reported after HCT. Although post-HCT cancers have
been reported to the DBAR, data are insufficient to define the
risk of cancer after HCT; however it may be higher than the
risk without HCT [93].
An Outline for Future Research in DBA
Reports on both short- and long-term outcomes in DBA
also lag far behind the number of reports that now exist for
FA. A number of key research priorities moving forward have
been identified, including the following:
1. Analysis of all available data is the key to accurate HCT
outcome assessment. Data from the CIBMTR and the DBAR
may have 70% to 80% of patients with DBA and HCT re-
ported but must be linked to avoid likely duplication of
these rare patients. These data sets were not established
to discern the nuances of DBA in the context of trans-
plantation. Furthermore, the data collected are
complementary, so the data sets must be merged for an
effective analysis.
2. Larger more meaningful studies, which will require ap-
propriate funding for more specific data collection, need
new revised forms for DBAR, CIBMTR, and EBMT or other
international registry collaborations. In particular, de-
tailed genotypic data may reveal at-risk genotypes and
correlations of outcomes with iron burden and prior cor-
ticosteroid therapy need to be documented.
3. Most importantly, increased collaboration between the
BMF expert and the stem cell transplantation physician
is imperative to appropriately analyze outcomes as well
as care for the patients with DBA.
IMPORTANT METHODOLOGIC CHALLENGES IN FUTURE
STUDIES OF LATE EFFECTS OF IBMFS
Two questions that one should start with when plan-
ning future studies of late effects in IBMFS are (1) what are
the major late effects after HCT, and (2) which are related to
the transplantation itself or are part of the natural history
of the syndrome? The analyses should be stratified accord-
ing to the specific syndrome, the reason for the HCT (eg,
aplastic anemia, MDS, or leukemia), the preparative regimen,
source of stem cells, and type and extent of GVHD if it oc-
curred. Ideally, comparison groups should include patients
who have and have not undergone transplantation with the
same syndrome, 1 syndrome versus another, or the syn-
drome versus the general population. If cancer risks are
studied, comparison of risks with the general population
would provide standardized incidence rates. Data could
include the cumulative incidence of late effects or mortali-
ty, using age rather than interval from transplantation as the
time course, to determine the impact of the transplantation
on the trajectory to an event for which patients with a spe-
cific IBMFS may have an intrinsic risk.
Most important to understanding the role of HCT in late
effects is to avoid bias by using the appropriate time scale
(age), keeping all data current, minimal patients “lost to
follow-up”, common protocols for data collection and anal-
yses, and consideration of time trends (older versus recent
treatment modalities) and of birth cohort effects. Analyses
can be actuarial, in which the censored subjects are implied
to be representative of those who remain in the study. Com-
peting risks, in which experience of an event may change the
risk of another event, should be addressed.
Studies can be retrospective, cross-sectional, or prospec-
tive, and data may come from large cohorts, consortia of
cohorts, or existing registries such as CIBMTR and EBMTR. It
is vital to have cohorts of patients who have not undergone
transplantation that are as close as possible to those who have,
with the caveat that transplantations are done for clinical in-
dications or anticipated indications, and those subjects may
therefore be intrinsically different from those who have not
had an HCT.
CONCLUSION
This review discusses the current state of knowledge re-
garding long-term follow-up of patients with FA, DC, and DBA
after HCT. In addition, we outline an agenda for future re-
search to address key missing data needed to further define
long-term effects and possibly lead to trials that could either
prevent or mitigate specific effects. In a subsequent publi-
cation, this working group will provide specific screening
guidelines for these 3 diseases. Because of time constraints,
it was not possible to address many other forms of IBMFS
through this consensus conference. There was recognition of
the need to also work on continued understanding and con-
sensus recommendations for other IBMFS as we move
forward.
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